Vasopressor resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 21: | Line 21: | ||
{{Family tree | | | | | | | | | | | | | |!| | | | | | | | }} | {{Family tree | | | | | | | | | | | | | |!| | | | | | | | }} | ||
{{Family tree | | | | | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | |}} | {{Family tree | | | | | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | |}} | ||
{{Family tree | | | | | B01 | | B02 | | B03 | | B04 | | B05 | |B01='''Norepinephrine''' |B02='''Dopamine''' |B03='''Vasopressin''' |B04='''Phenylephrine'''|B05='''Dobutamine''' }} | {{Family tree | | | | | B01 | | B02 | | B03 | | B04 | | B05 | |B01='''[[Norepinephrine]]''' |B02='''[[Dopamine]]''' |B03='''[[Vasopressin]]''' |B04='''[[Phenylephrine]]'''|B05='''[[Dobutamine]]''' }} | ||
{{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | {{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | ||
{{Family tree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | |C01= '''Mechanism''' |C02= *Mainly predominant'''α1''' agonist (Vasoconstrictive) <br> *some β1 agonist (↑contractility) |C03= *Mainly predominant '''β1''' agonist (↑contractility) <br> * some α1 agonist(Vasoconstrictive)|C04= *'''V<sub></sub>1''' receptor of GIT vasculatures <br> *Antidiuretic effects |C05= *'''Pure α1''' agonist(Vasoconstrictive) <br> *No β1 |C06= *Mainly predominant '''β1''' agonist (↑contractility) <br> *β2 arterial smooth muscle (Hypotensive) }} | {{Family tree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | |C01= '''Mechanism''' |C02= *Mainly predominant'''α1''' agonist (Vasoconstrictive) <br> *some β1 agonist (↑contractility) |C03= *Mainly predominant '''β1''' agonist (↑contractility) <br> * some α1 agonist(Vasoconstrictive)|C04= *'''V<sub></sub>1''' receptor of GIT vasculatures <br> *Antidiuretic effects |C05= *'''Pure α1''' agonist(Vasoconstrictive) <br> *No β1 |C06= *Mainly predominant '''β1''' agonist (↑contractility) <br> *β2 arterial smooth muscle (Hypotensive) }} | ||
| Line 31: | Line 31: | ||
{{Family tree | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | |F01= '''Complications''' |F02= Tachyarrhythmia less than Dopamine (less β1 effect) |F03= Arrhythmia (more β1) |F04= *Coronary spasm<br>*Splanchnic vasoconstriction|F05= Reflex bradycardia <br> (no worsening of tachycardia) <br>(only α1) |F06= Hypotension (β2) }} | {{Family tree | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | |F01= '''Complications''' |F02= Tachyarrhythmia less than Dopamine (less β1 effect) |F03= Arrhythmia (more β1) |F04= *Coronary spasm<br>*Splanchnic vasoconstriction|F05= Reflex bradycardia <br> (no worsening of tachycardia) <br>(only α1) |F06= Hypotension (β2) }} | ||
{{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | {{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | ||
{{Family tree | G01 | | G02 | | G03 | | G04 | | G05 | | G06 | |G01= '''Cautions''' |G02= Arrhythmia |G03= *Not in cardiogenic shock <br>*Arrhythmia <br> *cardiotoxicity with ischemia |G04= *Ischemic heart | {{Family tree | G01 | | G02 | | G03 | | G04 | | G05 | | G06 | |G01= '''Cautions''' |G02= Arrhythmia |G03= *Not in cardiogenic shock <br>*Arrhythmia <br> *cardiotoxicity with ischemia |G04= *Ischemic heart <br> *Gut ischemia |G05= *Bradycardia <br> *Heart block |G06= *Hypotension (add α1 agonist) }} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
Revision as of 16:17, 6 December 2013
|
Sepsis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Vasopressor resident survival guide On the Web |
|
American Roentgen Ray Society Images of Vasopressor resident survival guide |
|
Risk calculators and risk factors for Vasopressor resident survival guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Definition
Causes
Life Threatening Causes
Common Causes
Prognosis
Management
| Vasopressors | |||||||||||||||||||||||||||||||||||||||||||||||||
| Norepinephrine | Dopamine | Vasopressin | Phenylephrine | Dobutamine | |||||||||||||||||||||||||||||||||||||||||||||
| Mechanism | *Mainly predominantα1 agonist (Vasoconstrictive) *some β1 agonist (↑contractility) | *Mainly predominant β1 agonist (↑contractility) * some α1 agonist(Vasoconstrictive) | *V1 receptor of GIT vasculatures *Antidiuretic effects | *Pure α1 agonist(Vasoconstrictive) *No β1 | *Mainly predominant β1 agonist (↑contractility) *β2 arterial smooth muscle (Hypotensive) | ||||||||||||||||||||||||||||||||||||||||||||
| Indication | *1st line in : *Septic shock *Cardiogenic shock *Undifferentiated shock | 2nd line septic shock | 2nd line septic shock | 1st line Neurogenic shock 3rd-4th line septic shock | *1st line cardiogenic shock * low output septic shock | ||||||||||||||||||||||||||||||||||||||||||||
| Dose | 1-30 mcg/kg/min | 1-20 mcg/min | 0.03 unit/min | 20-300 mcg/kg/min | 2.5-20 mcg/kg/min | ||||||||||||||||||||||||||||||||||||||||||||
| Complications | Tachyarrhythmia less than Dopamine (less β1 effect) | Arrhythmia (more β1) | *Coronary spasm *Splanchnic vasoconstriction | Reflex bradycardia (no worsening of tachycardia) (only α1) | Hypotension (β2) | ||||||||||||||||||||||||||||||||||||||||||||
| Cautions | Arrhythmia | *Not in cardiogenic shock *Arrhythmia *cardiotoxicity with ischemia | *Ischemic heart *Gut ischemia | *Bradycardia *Heart block | *Hypotension (add α1 agonist) | ||||||||||||||||||||||||||||||||||||||||||||
Do's
- Assess the cause of shock
- Always volume fluid resuscitation first
- Norepinephrine in undifferentiated shock.